Told you so.. Salazar-Camelo A, Vega L, Fadlallah Y, Bou Rjeily N, Balshi A, Morris B, Ghajarzadeh M, Mowry EM, Waubant E, Nourbakhsh B. Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls. Mult Scler. 2025 Sep 19:13524585251375350. doi: 10.1177/13524585251375350. Epub ahead of print. PMID: 40970353. Background: Whether continuous anti-CD20 therapy is required […]
https://multiple-sclerosis-res....earch.org/2025/09/to

How does CD20 work?What next the Questioning B cell? When I was a kid we had a few PC descriptors for non-heterosexual identifying people and now whe have LGBTQIA+ and an every expanding acronym. Yep you ask what has this got to do with MS research. We have anti-CD20 antibodies which are increasingly used and is the major high efficacy class of treatment used […]
https://multiple-sclerosis-res....earch.org/2025/09/ho

How does CD20 work?What next the Questioning B cell? When I was a kid we had a few PC descriptors for non-heterosexual identifying people and now whe have LGBTQIA+ and an every expanding acronym. Yep you ask what has this got to do with MS research. We have anti-CD20 antibodies which are increasingly used and is the major high efficacy class of treatment used […]
https://multiple-sclerosis-res....earch.org/2025/09/ho